Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor
暂无分享,去创建一个
Zhiping Weng | Brian G. Pierce | Lance M. Hellman | Moushumi Hossain | Nishant K. Singh | Craig W. Vander Kooi | Brian M. Baker | Z. Weng | B. Pierce | L. Hellman | N. Singh | B. Baker | C. V. Kooi | M. Hossain | Moushumi Hossain
[1] Zhiping Weng,et al. Backbone flexibility of CDR3 and immune recognition of antigens. , 2014, Journal of molecular biology.
[2] Jennifer A. McWilliams,et al. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. , 2006, The Journal of clinical investigation.
[3] Zhiping Weng,et al. Structure‐based design of a T‐cell receptor leads to nearly 100‐fold improvement in binding affinity for pepMHC , 2009, Proteins.
[4] Brian Kuhlman,et al. Computational design of second‐site suppressor mutations at protein–protein interfaces , 2010, Proteins.
[5] Brian M Baker,et al. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. , 2007, Journal of molecular biology.
[6] J Alexander,et al. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. , 2002, Tissue antigens.
[7] Julie C. Mitchell,et al. Community‐wide evaluation of methods for predicting the effect of mutations on protein–protein interactions , 2013, Proteins.
[8] S. Rosenberg,et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails , 2013, Cancer Immunology, Immunotherapy.
[9] J. Thornton,et al. Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.
[10] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[11] Z. Weng,et al. Combinations of affinity-enhancing mutations in a T cell receptor reveal highly nonadditive effects within and between complementarity determining regions and chains. , 2010, Biochemistry.
[12] R. Mariuzza,et al. Structural basis for self‐recognition by autoimmune T‐cell receptors , 2012, Immunological reviews.
[13] Adam Bagg,et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.
[14] P. Katsamba,et al. Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.
[15] David M. Kranz,et al. Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies , 2013, Front. Immunol..
[16] Olivier Michielin,et al. Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness* , 2012, The Journal of Biological Chemistry.
[17] Daniel Coombs,et al. Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time , 2010, Immunity.
[18] J. Boulter,et al. Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. , 2007, Protein engineering, design & selection : PEDS.
[19] David M Kranz,et al. Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[20] Tirso Pons,et al. Homology modeling, model and software evaluation: three related resources , 1998, Bioinform..
[21] Zhiping Weng,et al. Cutting Edge: Evidence for a Dynamically Driven T Cell Signaling Mechanism , 2012, The Journal of Immunology.
[22] D. Kranz,et al. T‐cell receptor binding affinities and kinetics: impact on T‐cell activity and specificity , 2009, Immunology.
[23] B. Baker,et al. Disparate degrees of hypervariable loop flexibility control T-cell receptor cross-reactivity, specificity, and binding mechanism. , 2011, Journal of molecular biology.
[24] Yi Li,et al. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide‐MHC without increasing apparent cross‐reactivity , 2006, Protein science : a publication of the Protein Society.
[25] Z. Weng,et al. Main‐chain conformational tendencies of amino acids , 2005, Proteins.
[26] K D Wittrup,et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] Brian M Baker,et al. Two different T cell receptors use different thermodynamic strategies to recognize the same peptide/MHC ligand. , 2005, Journal of molecular biology.
[28] D. Baker,et al. A simple physical model for binding energy hot spots in protein–protein complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[29] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[30] K. Garcia,et al. How a Single T Cell Receptor Recognizes Both Self and Foreign MHC , 2007, Cell.
[31] B. Baker,et al. Increased Immunogenicity of an Anchor-Modified Tumor-Associated Antigen Is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design1 , 2005, The Journal of Immunology.
[32] Robyn L Stanfield,et al. How TCRs bind MHCs, peptides, and coreceptors. , 2006, Annual review of immunology.
[33] V. Zoete,et al. MM–GBSA binding free energy decomposition and T cell receptor engineering , 2010, Journal of molecular recognition : JMR.
[34] Zhiping Weng,et al. Prediction of protein–protein binding free energies , 2012, Protein science : a publication of the Protein Society.
[35] Pierre Baldi,et al. A CROC stronger than ROC: measuring, visualizing and optimizing early retrieval , 2010, Bioinform..
[36] S. Rosenberg,et al. Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy , 2010, Clinical Cancer Research.
[37] S. Rosenberg,et al. Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 , 2006, The Journal of Immunology.
[38] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[39] Partho Ghosh,et al. The Structure and Stability of an HLA-A*0201/Octameric Tax Peptide Complex with an Empty Conserved Peptide-N-Terminal Binding Site1 , 2000, The Journal of Immunology.
[40] Vincent B. Chen,et al. Correspondence e-mail: , 2000 .
[41] G. Gao,et al. Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor* , 2009, The Journal of Biological Chemistry.
[42] Bent K. Jakobsen,et al. Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.
[43] K. Garcia,et al. Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors. , 2008, Biochemistry.
[44] Zhiping Weng,et al. ZRANK: Reranking protein docking predictions with an optimized energy function , 2007, Proteins.
[45] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Yi Li,et al. Design of Soluble Recombinant T Cell Receptors for Antigen Targeting and T Cell Inhibition* , 2005, Journal of Biological Chemistry.
[47] Yvonne McGrath,et al. Monoclonal TCR-redirected tumor cell killing , 2012, Nature Medicine.
[48] Kurt H Piepenbrink,et al. T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. , 2009, Immunity.
[49] Brian M. Baker,et al. The basis for limited specificity and MHC restriction in a T cell receptor interface , 2013, Nature Communications.
[50] Randy J. Read,et al. Iterative-build OMIT maps: map improvement by iterative model building and refinement without model bias , 2008, Acta crystallographica. Section D, Biological crystallography.
[51] Nicholas A Williamson,et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule , 2007, Nature Immunology.
[52] Z. Weng,et al. A flexible docking approach for prediction of T cell receptor–peptide–MHC complexes , 2013, Protein science : a publication of the Protein Society.
[53] Yi Li,et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display , 2005, Nature Biotechnology.
[54] J. Allison,et al. Attenuated T Cell Responses to a High-Potency Ligand In Vivo , 2010, PLoS biology.
[55] Andrew Leaver-Fay,et al. A Generic Program for Multistate Protein Design , 2011, PloS one.
[56] B. Baker,et al. TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms , 2011, The Journal of Immunology.
[57] Brian M. Baker,et al. Conformational changes and flexibility in T-cell receptor recognition of peptide–MHC complexes , 2008, The Biochemical journal.
[58] Steven A. Rosenberg,et al. Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.
[59] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[60] Yi Li,et al. T-cell Receptor Specificity Maintained by Altered Thermodynamics* , 2013, The Journal of Biological Chemistry.
[61] Gregory Lizée,et al. Harnessing the power of the immune system to target cancer. , 2013, Annual review of medicine.
[62] David M Kranz,et al. Long-range cooperative binding effects in a T cell receptor variable domain. , 2006, Proceedings of the National Academy of Sciences of the United States of America.